KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exact Sciences (EXAS) Shares Outstanding (Diluted Average) (2019 - 2025)

Exact Sciences (EXAS) has disclosed Shares Outstanding (Diluted Average) for 10 consecutive years, with $188.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 2.44% to $188.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $188.7 million through Dec 2025, up 2.44% year-over-year, with the annual reading at $188.7 million for FY2025, 2.44% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $188.7 million at Exact Sciences, roughly flat from $188.3 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $188.9 million in Q2 2025, with the low at $169.4 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $179.9 million, with a median of $180.2 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) increased 14.54% in 2021, then fell 0.14% in 2024.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $171.3 million in 2021, then rose by 2.92% to $176.4 million in 2022, then grew by 2.15% to $180.1 million in 2023, then grew by 2.25% to $184.2 million in 2024, then increased by 2.44% to $188.7 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $188.7 million, $188.3 million, and $188.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.